Tech Company Financing Transactions
Renibus Therapeutics Funding Round
On 7/19/2023, Renibus Therapeutics raised $47 million in Series B funding from private investors.
Transaction Overview
Company Name
Announced On
7/19/2023
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance RBT-1 through a pivotal Phase 3 trial for its lead indication of reducing the risk of post-operative complications following cardiothoracic surgery.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
181 Grand Ave. 225
Southlake, TX 76092
USA
Southlake, TX 76092
USA
Phone
Website
Email Address
Overview
We are dedicated to treating, improving and extending patients' lives by developing breakthrough products to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Frank Stonebanks
Chief Financial Officer
Jamie Donadio
Chief Medical Officer
Bhupinder Singh
President
Jeff Keyser
Browse more venture capital transactions:
Prev: 7/19/2023: SiPhox Health venture capital transaction
Next: 7/19/2023: Verse Inc venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs